SEQUOIA-HCM trial meets primary endpoint in obstructive hypertrophic cardiomyopathy
Lisbon, Portugal – 13 May 2024: Even though mortality and hospitalisation rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional dyspnoea and decreased …